Multiple Myeloma Inhibitory Activity of Plant Natural Products

• Published in: Cancers 2021-05, Vol.13 (11), p.2678
• Main Authors: Jöhrer, Karin, Ҫiҫek, Serhat Sezai
• Format: Article
• Language: English
• Subjects: Alkaloids; Apoptosis; Bone marrow; Bortezomib; Cell cycle; Cell growth; Chymotrypsin; Diterpenes; Drug development; Drugs; Indexing services; Investigations; Multiple myeloma; Natural products; NF-κB protein; Phenolic compounds; Proteasomes; Quinones; Review; Terpenes; Triterpenoids
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13112678

A literature search on plant natural products with antimyeloma activity until the end of 2020 resulted in 92 compounds with effects on at least one human myeloma cell line. Compounds were divided in different compound classes and both their structure-activity-relationships as well as eventual correlations with the pathways described for Multiple Myeloma were discussed. Each of the major compound classes in this review (alkaloids, phenolics, terpenes) revealed interesting candidates, such as dioncophyllines, a group of naphtylisoquinoline alkaloids, which showed pronounced and selective induction of apoptosis when substituted in position 7 of the isoquinoline moiety. Interestingly, out of the phenolic compound class, two of the most noteworthy constituents belong to the relatively small subclass of xanthones, rendering this group a good starting point for possible further drug development. The class of terpenoids also provides noteworthy constituents, such as the highly oxygenated diterpenoid oridonin, which exhibited antiproliferative effects equal to those of bortezomib on RPMI8226 cells. Moreover, triterpenoids containing a lactone ring and/or quinone-like substructures, e.g., bruceantin, whitaferin A, withanolide F, celastrol, and pristimerin, displayed remarkable activity, with the latter two compounds acting as inhibitors of both NF-κB and proteasome chymotrypsin-like activity.